Stocks · Health care · Pharmaceutical Preparations

Corbus Pharmaceuticals Holdings, Inc.

CRBP Clue Score27
United States Fiscal year ends December CIK 0001595097 Results filed 6 Aug 2026

What the insiders did Net buying

Insider
Date
Role
Action
Shares
Price
Amount
Yuval Cohen
27 Oct 2025
Chief Executive Officer
Sold after exercise
8,973
$17.14
$153.80K
Sean F. Moran
24 Oct 2025
Chief Financial Officer
Sold after exercise
12,981
$17.02
$220.94K
Yuval Cohen
24 Oct 2025
Chief Executive Officer
Sold after exercise
18,660
$17.01
$317.41K
Anne Altmeyer
20 Oct 2025
Director
Sold after exercise
1,060
$20.50
$21.73K
Yuval Cohen
18 Jun 2024
Chief Executive Officer
Sold after exercise
7,179
$42.24
$303.22K
Yuval Cohen
18 Jun 2024
Chief Executive Officer
Sold after exercise
2,322
$42.24
$98.07K
Yuval Cohen
18 Jun 2024
Chief Executive Officer
Sold after exercise
1,770
$42.24
$74.76K
Yuval Cohen
18 Jun 2024
Chief Executive Officer
Sold after exercise
11,667
$42.24
$492.78K
Sean F. Moran
18 Jun 2024
Chief Financial Officer
Sold after exercise
1,958
$42.12
$82.48K
Yuval Cohen
17 Jun 2024
Chief Executive Officer
Sold after exercise
1,770
$46.02
$81.46K
Yuval Cohen
17 Jun 2024
Chief Executive Officer
Sold after exercise
9,333
$46.02
$429.51K
Sean F. Moran
17 Jun 2024
Chief Financial Officer
Sold after exercise
6,730
$46.77
$314.79K
Yuval Cohen
14 Jun 2024
Chief Executive Officer
Sold after exercise
12,487
$50.17
$626.43K
Yuval Cohen
14 Jun 2024
Chief Executive Officer
Sold after exercise
16,830
$50.17
$844.30K
Sean F. Moran
14 Jun 2024
Chief Financial Officer
Sold after exercise
7,788
$49.87
$388.42K
Sean F. Moran
14 Jun 2024
Chief Financial Officer
Sold after exercise
1,567
$49.87
$78.15K
Sean F. Moran
21 Dec 2020
Chief Financial Officer
Sold after exercise
87,500
$1.75
$153.13K
Sean F. Moran
18 Dec 2020
Chief Financial Officer
Sold after exercise
53,610
$1.40
$75.05K
Sean F. Moran
16 Dec 2020
Chief Financial Officer
Sold after exercise
36,923
$1.32
$48.63K

What was left out

Form 4 filings counted 216
Amendments (4/A) skipped 2
Filings about a different issuer 0
Unreadable filings 0
Joint filings 6
Sales on a Rule 10b5-1 plan 12
Sales straight out of an exercise 19
Sales at will 7
Transactions with no price 0
Shares from compensation/vesting 1,398,906
History held since 26 Nov 2014